Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection
Prabhakaran Kumar, Manikannan Mathayan, Sandra Smieszek, Bartlomiej Przychodzen, Vuk Koprivica, Gunther Birznieks, Mihael H. Polymeropoulos, Bellur S. Prabhakar
Topics & Concepts
RepurposingDrugBiologyCoronavirus disease 2019 (COVID-19)PharmacologyDrug repositioningCrizotinibSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical trialComputational biologyVirologyBioinformaticsMedicineInfectious disease (medical specialty)Internal medicineDiseasePleural effusionMalignant pleural effusionEcologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesPARP inhibition in cancer therapy